SMMT
Summit Therapeutics Inc.
NASDAQHealthcareBiotechnologyUS
Rating:C
Company Profile
CEO
Robert W. Duggan
IPO Date
2015-03-05
Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
Country
US
Summit Therapeutics Inc.
CEO
Robert W. Duggan
IPO Date
2015-03-05
Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
Country
US
| Acquired |
| 3,810,000 |
| $13.12 |
| 4 Jun 2026 | DUGGAN ROBERT W | director, 10 percent owner, officer: Co-Chief Executive Officer | P-Purchase | Acquired | 100,000 | $14.60 |
| 4 Jun 2026 | Zanganeh Mahkam | director, 10 percent owner, officer: Co-Chief Executive Officer | P-Purchase | Acquired | 100,000 | $14.60 |
| 4 Jun 2026 | Soni Manmeet Singh | director, officer: COO and CFO | P-Purchase | Acquired | 25,000 | $14.46 |
| 4 Jun 2026 | Soni Manmeet Singh | director, officer: COO and CFO | P-Purchase | Acquired | 25,000 | $14.43 |
| 12 Jan 2026 | Anand Bhaskar | Chief Accounting Officer | A-Award | Acquired | 30,000 | $18.83 |
| 6 Jan 2026 | Zanganeh Mahkam | director, 10 percent owner, officer: Co-Chief Executive Officer | A-Award | Acquired | 11,232 | $17.52 |
| 6 Jan 2026 | DUGGAN ROBERT W | director, 10 percent owner, officer: Co-Chief Executive Officer | A-Award | Acquired | 11,232 | $17.52 |
| 6 Jan 2026 | Booth Robert F. | director | A-Award | Acquired | 35,000 | $17.52 |